Enhancing the nutritional value of protein

We've developed patent-pending processing technology that improves the bioavailability and bioefficacy of protein.

Photo of Chris Flynn Rozanski
1 9

Written by

I confirm that I am fully aware of the eligibility criteria, and based on its description, I am eligible to apply to the CSV Prize 2017.

  • Yes, I'm eligible

Preferred language

  • English

Organization name

Plasma Nutrition

Year founded


Initiative stage

  • Start-Up (a pilot that has just started operating)

Annual budget in 2017 (USD)

  • $100k - $250k

Number of beneficiaries impacted so far

  • 500 - 1,000

Organization type

  • For-profit

Secondary Focus Area

  • Nutrition

Headquarters location: Country

  • United States of America

Location(s) of impact

We are currently building out our technology in the United States but we're exploring global partnerships to help expand our international reach.



Facebook URL


Problem: What problem is this initiative trying to address?

Protein malnutrition is a significant problem in both the developed and developing world, despite protein being a fundamental building block for health. Sarcopenia (old age muscle loss) is a growing problem as global populations age rapidly. On the other hand, protein deficiencies such as kwashiorkor impact millions of lives including children around the world. By improving the nutritional value of protein, we can make access to sufficient daily protein a possibility across all forms of protein deficiency.

Solution Summary: What is the proposed solution? What do you see as its most promising aspects for creating shared value?

We have developed patent-pending hardware and an accompanying process that improves the bioavailability and bioefficacy of proteins in powdered form. Through multiple human clinical trials, we've demonstrated our technologies effectiveness and are now working to apply it in multiple applications.

Impact: What is the impact of the work to date? Specify both the social and the environmental impact of your work

To date, our work has focused on technology development and clinical trials. From a business perspective, we have focused on partnerships in more accessible markets like sports nutrition that would allow us to validate our business model and technical scalability while also continuing our long term efforts in addressing significant clinical and medical nutrition objectives. According to the results of a university conducted study debuted in June 2017 by Dr. Bill Campbell, "Our data showed that one needs 26% less ioProtein in the post-workout period to achieve the same training adaptations as compared to standard whey protein isolate.” This is a critical finding for the possible use in clinical nutrition. Inability to intake food in high volume afflicts those across the protein deficient spectrum. More bioavailable protein would allow for the development of more compact, nutrient dense foods and supplements that could also be more easily transported into areas struggling with access.

Financial sustainability plan: How is this initiative financially supported? How will you ensure its financial sustainability long-term?

In an effort to achieve long-term sustainability, we have launched our technology first in the sports nutrition category. Through these partnerships, we've been able to fund our R&D objectives through early-stage revenue while maintaining our focus as a technology-focused company.

Unique value proposition: What makes your initiative innovative? How does your project differ from other organizations working in the same field?

Our technology is highly scalable and is designed for possible use across many protein sources, both animal and plant based, enabling our technology to serve various population segments. By improving protein in powdered form, this technology allows for use across various end product formulations and applications including beverages, functional foods, snacks, powders, etc.

Founding story: Share a story about the "Aha!" moment that sparked the beginning of this initiative.

Steve Motosko was researching plasma technology for his previous startup. Although it proved too expensive for his needs at the time, his fascination with alternative applications drove him to continue his research. Two years later, Motosko’s grandmother’s health began to deteriorate rapidly as a result of sarcopenia - a disease that causes extreme physical weakness and cripples quality of life. He met Co-Founder Chris Flynn in 2013 while working at one of New York City’s fastest growing startups where they often discussed the impact they wanted their careers to have on the world. During one of these conversations, Flynn mentioned his experiences with malnutrition and his desire to help those suffering from nutritional deficiencies. At that moment, they knew they had to apply plasma science to food and nutrition, so that they could help eliminate protein deficiency around the world.

Where did you hear about the Nestlé Creating Shared Value Prize?

  • Upon recommendation from others

1 comment

Join the conversation:

Photo of Julie Hanta Razafimanahaka

Dear Flynn,
Do you already have a plan for sharing this technology in developing world? Let me know if you are interested in trying it in Madagascar.